[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:cystic-fibrosis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":313,"states":322},"Cystic Fibrosis",98,77,[8,16,23,29,35,41,47,53,59,66,72,79,85,92,98,104,110,116,122,129,135,141,147,153,160,166,172,177,183,189,194,200,206,212,218,224,230,236,242,248,254,260,266,271,277,283,289,295,301,307],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05504837","A Study Assessing KB407 for the Treatment of Cystic Fibrosis",[12],"Phase 1","RECRUITING","2026-08-26T02:18:58.958025Z","2026-07-05T05:32:16.803851Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06429176","Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis",[20],"Phase 2","2026-08-26T02:17:57.997171Z","2026-07-05T05:32:16.753730Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06747858","Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis",[20],"2026-08-26T02:17:06.985283Z","2026-07-05T05:32:16.691189Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07450547","Phase 2 Study to Assess the Safety and Efficacy of ANG003",[20],"2026-08-26T02:18:51.833592Z","2026-05-13T02:55:06.705521Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06617013","GERD in Children With Cystic Fibrosis",[],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:29.381312Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT04530383","Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function",[20],"2026-08-26T02:17:18.747857Z","2026-05-05T02:43:29.214770Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT07275905","Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection",[12],"2026-08-26T02:15:49.658025Z","2026-05-05T02:43:29.214458Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06654752","Streamlined Treatment of Pulmonary Exacerbations in Pediatrics",[],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:28.881471Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":64,"content_modified":65},"NCT06413368","Maralixibat in Patients With Cystic Fibrosis and Constipation",[63],"Phase 2\u002FPhase 3","2026-08-26T02:17:07.954622Z","2026-05-05T02:43:28.881366Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06364176","Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.",[20],"2026-08-26T02:18:09.641312Z","2026-05-05T02:43:28.869930Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":77,"content_modified":78},"NCT03587961","Personalized Theratyping Trial",[76],"Early Phase 1","2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.839209Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07437105","Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:28.819098Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":90,"content_modified":91},"NCT06810167","Assessing Tenapanor as a Treatment of CF-related Constipation.",[89],"Phase 3","2026-08-03T02:15:56.082035Z","2026-05-05T02:43:28.811377Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT05723445","The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes",[],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:28.733419Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06616857","Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis",[],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.658482Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT05248230","4D-710 in Adult Patients With Cystic Fibrosis",[20],"2026-08-26T02:15:22.311223Z","2026-05-05T02:43:28.560560Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT06237335","A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF",[20],"2026-08-03T03:27:47.777467Z","2026-05-05T02:43:28.540558Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT07071324","CF Wellness Program",[],"2026-08-26T02:17:21.315591Z","2026-05-05T02:43:28.191166Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":127,"content_modified":128},"NCT06526923","A Phase 1\u002F2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)",[126],"Phase 1\u002FPhase 2","2026-08-26T02:16:32.589113Z","2026-05-05T02:43:28.129418Z",{"nct_id":130,"title":131,"phases":132,"status":13,"updated_at":133,"content_modified":134},"NCT07283770","Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants",[12],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:28.123821Z",{"nct_id":136,"title":137,"phases":138,"status":13,"updated_at":139,"content_modified":140},"NCT04580368","Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials",[],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:27.993194Z",{"nct_id":142,"title":143,"phases":144,"status":13,"updated_at":145,"content_modified":146},"NCT06998043","Study With Phage for CF Subjects With Pseudomonas Lung Infection",[20],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:27.952993Z",{"nct_id":148,"title":149,"phases":150,"status":13,"updated_at":151,"content_modified":152},"NCT04294043","IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)",[12],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:27.842010Z",{"nct_id":154,"title":155,"phases":156,"status":13,"updated_at":158,"content_modified":159},"NCT07148739","Ensuring Access to Optimal Therapy in CF: The ENACT Study",[157],"Phase 4","2026-08-26T02:15:37.042762Z","2026-05-05T02:43:27.661557Z",{"nct_id":161,"title":162,"phases":163,"status":13,"updated_at":164,"content_modified":165},"NCT05704036","Estrogen Supplementation and Bone Health in Women With CF",[157],"2026-08-26T02:19:31.671303Z","2026-05-05T02:43:27.517290Z",{"nct_id":167,"title":168,"phases":169,"status":13,"updated_at":170,"content_modified":171},"NCT06996951","Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy",[89],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:27.178230Z",{"nct_id":173,"title":174,"phases":175,"status":13,"updated_at":133,"content_modified":176},"NCT05548283","Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study",[157],"2026-05-05T02:43:26.905383Z",{"nct_id":178,"title":179,"phases":180,"status":13,"updated_at":181,"content_modified":182},"NCT07436351","ACT With CF Self-Help Toolkit",[],"2026-08-26T02:18:39.640967Z","2026-05-05T02:43:28.370656Z",{"nct_id":184,"title":185,"phases":186,"status":13,"updated_at":187,"content_modified":188},"NCT05766774","FEED-Cystic Fibrosis (FEED-CF)",[],"2026-08-26T02:17:57.117858Z","2026-04-29T02:57:57.175412Z",{"nct_id":190,"title":191,"phases":192,"status":13,"updated_at":57,"content_modified":193},"NCT05517655","BEGIN Novel ImagiNG Biomarkers",[157],"2026-05-05T02:43:28.849403Z",{"nct_id":195,"title":196,"phases":197,"status":13,"updated_at":198,"content_modified":199},"NCT05998629","Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)",[],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:27.676882Z",{"nct_id":201,"title":202,"phases":203,"status":13,"updated_at":204,"content_modified":205},"NCT06339593","Regional Monitoring of CF Lung Disease",[76],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:27.665649Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT03921060","Markers of Osteoporosis in Cystic Fibrosis",[157],"2026-08-26T02:17:15.156099Z","2026-05-05T02:35:31.863051Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":216,"content_modified":217},"NCT04624490","Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease",[12],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:29.714235Z",{"nct_id":219,"title":220,"phases":221,"status":13,"updated_at":222,"content_modified":223},"NCT06512064","Acoustic Waveform Respiratory Evaluation",[],"2026-08-26T02:17:22.949982Z","2026-04-29T02:57:57.144745Z",{"nct_id":225,"title":226,"phases":227,"status":13,"updated_at":228,"content_modified":229},"NCT03161808","Rare CFTR Mutation Cell Collection Protocol (RARE)",[],"2026-08-26T02:17:22.153941Z","2026-07-05T05:32:16.769658Z",{"nct_id":231,"title":232,"phases":233,"status":13,"updated_at":234,"content_modified":235},"NCT07312734","Study to Enable New Diagnostics for Pulmonary Microbes in People With CF",[],"2026-08-26T02:17:30.145302Z","2026-05-13T02:55:06.685374Z",{"nct_id":237,"title":238,"phases":239,"status":13,"updated_at":240,"content_modified":241},"NCT07048574","TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age",[],"2026-08-26T02:16:42.787115Z","2026-05-13T02:55:06.608757Z",{"nct_id":243,"title":244,"phases":245,"status":13,"updated_at":246,"content_modified":247},"NCT06950892","Remote Sputum Collection in Cystic Fibrosis",[],"2026-08-26T02:19:12.219640Z","2026-05-13T02:55:06.593723Z",{"nct_id":249,"title":250,"phases":251,"status":13,"updated_at":252,"content_modified":253},"NCT06837181","Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)",[],"2026-08-26T02:15:23.202838Z","2026-05-13T02:55:06.584092Z",{"nct_id":255,"title":256,"phases":257,"status":13,"updated_at":258,"content_modified":259},"NCT06847256","Genetic Risk Factor for Heat Stroke",[],"2026-08-26T02:16:08.402952Z","2026-05-13T02:55:06.583445Z",{"nct_id":261,"title":262,"phases":263,"status":13,"updated_at":264,"content_modified":265},"NCT06831110","Aquagenic Wrinkling Prediction",[],"2026-08-26T02:18:03.638950Z","2026-05-13T02:55:06.582622Z",{"nct_id":267,"title":268,"phases":269,"status":13,"updated_at":108,"content_modified":270},"NCT06683092","Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)",[],"2026-05-13T02:55:06.562100Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":275,"content_modified":276},"NCT06587126","Feasibility of Cough Monitoring in Children",[],"2026-08-26T02:18:38.865010Z","2026-05-13T02:55:06.552008Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":281,"content_modified":282},"NCT06560463","Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis",[],"2026-08-26T02:17:39.857430Z","2026-05-13T02:55:06.502358Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":287,"content_modified":288},"NCT06546943","Glucose Monitoring in Youth With Cystic Fibrosis During Pulmonary Exacerbations",[],"2026-08-26T02:18:18.766496Z","2026-05-13T02:55:06.500003Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":293,"content_modified":294},"NCT06504589","A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators",[],"2026-08-26T02:19:14.560989Z","2026-05-13T02:55:06.496592Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":299,"content_modified":300},"NCT06296394","Health Outcomes of Parents With Cystic Fibrosis-Aim 2",[],"2026-08-26T02:18:26.932189Z","2026-05-13T02:55:06.433237Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":305,"content_modified":306},"NCT06216704","Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis",[],"2026-08-26T02:17:45.190188Z","2026-05-13T02:55:06.426379Z",{"nct_id":308,"title":309,"phases":310,"status":13,"updated_at":311,"content_modified":312},"NCT06066723","19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease",[],"2026-08-26T02:19:20.945539Z","2026-05-13T02:55:06.405917Z",[314,318],{"biomarker":315,"count":316,"slug":317},"CFTR Gene",21,"cftr-gene",{"biomarker":319,"count":320,"slug":321},"Cystic fibrosis sweat test",3,"cystic-fibrosis-sweat-test",[323,327,330,334,338,342,346,350,354,358,362,365,368,372,376,379,382,386,389,393,396,400,403,406],{"state":324,"count":325,"slug":326},"Colorado",29,"colorado",{"state":328,"count":325,"slug":329},"Massachusetts","massachusetts",{"state":331,"count":332,"slug":333},"California",27,"california",{"state":335,"count":336,"slug":337},"Pennsylvania",26,"pennsylvania",{"state":339,"count":340,"slug":341},"Ohio",25,"ohio",{"state":343,"count":344,"slug":345},"Maryland",23,"maryland",{"state":347,"count":348,"slug":349},"Texas",22,"texas",{"state":351,"count":352,"slug":353},"Alabama",20,"alabama",{"state":355,"count":356,"slug":357},"New York",19,"new-york",{"state":359,"count":360,"slug":361},"Florida",18,"florida",{"state":363,"count":360,"slug":364},"Kansas","kansas",{"state":366,"count":360,"slug":367},"Washington","washington",{"state":369,"count":370,"slug":371},"North Carolina",16,"north-carolina",{"state":373,"count":374,"slug":375},"Georgia",14,"georgia",{"state":377,"count":374,"slug":378},"Minnesota","minnesota",{"state":380,"count":374,"slug":381},"Missouri","missouri",{"state":383,"count":384,"slug":385},"Illinois",13,"illinois",{"state":387,"count":384,"slug":388},"Indiana","indiana",{"state":390,"count":391,"slug":392},"South Carolina",12,"south-carolina",{"state":394,"count":391,"slug":395},"Virginia","virginia",{"state":397,"count":398,"slug":399},"Arizona",10,"arizona",{"state":401,"count":398,"slug":402},"Iowa","iowa",{"state":404,"count":398,"slug":405},"Wisconsin","wisconsin",{"state":407,"count":408,"slug":409},"Michigan",9,"michigan"]